Literature DB >> 7597800

Endogenous retroviruses in the human genome--a point of view.

Y Becker1.   

Abstract

The search for retroviruses in human cancer cells has advanced with the discoveries of the retroviral reverse transcriptase, DNA hybridization and sequencing techniques, and polymerase chain reaction (PCR) technology. Each technological advancement has led to a better refinement and a better understanding of latent endogenous retroviruses in the human genome. With the recent developments in the Human Genome Project it is to be expected that additional information will be obtained on the role and function of these human retroviruses, their ancestral origin and, if possible, their involvement as a source for emerging new retroviruses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7597800     DOI: 10.1007/BF01702877

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  44 in total

1.  RNA-dependent DNA polymerase in virions of RNA tumour viruses.

Authors:  D Baltimore
Journal:  Nature       Date:  1970-06-27       Impact factor: 49.962

2.  RNA-dependent DNA polymerase in virions of Rous sarcoma virus.

Authors:  H M Temin; S Mizutani
Journal:  Nature       Date:  1970-06-27       Impact factor: 49.962

3.  Human leukaemic cells contain reverse transcriptase associated with a high molecular weight virus-related RNA.

Authors:  W Baxt; R Hehlmann; S Spiegelman
Journal:  Nat New Biol       Date:  1972-11-15

4.  Detection of oncornavirus-like particles in HeLa cells. I. Fine structure and comparative morphological classification.

Authors:  H Gelderblom; H Bauer; H Ogura; R Wigand; A B Fischer
Journal:  Int J Cancer       Date:  1974-02-15       Impact factor: 7.396

5.  A general method for the identification of transcribed retrovirus sequences (R-U5 PCR) reveals the expression of the human endogenous retrovirus loci HERV-H and HERV-K in teratocarcinoma cells.

Authors:  R Löwer; J Löwer; C Tondera-Koch; R Kurth
Journal:  Virology       Date:  1993-02       Impact factor: 3.616

6.  Sequence variation of human endogenous retrovirus ERV9-related elements in an env region corresponding to an immunosuppressive peptide: transcription in normal and neoplastic cells.

Authors:  M Lindeskog; P Medstrand; J Blomberg
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

7.  The human endogenous retrovirus ERV-3 is upregulated in differentiating placental trophoblast cells.

Authors:  M T Boyd; C M Bax; B E Bax; D L Bloxam; R A Weiss
Journal:  Virology       Date:  1993-10       Impact factor: 3.616

8.  Evidence for a functional subclass of the RTVL-H family of human endogenous retrovirus-like sequences.

Authors:  D A Wilkinson; N L Goodchild; T M Saxton; S Wood; D L Mager
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  ERV3, a full-length human endogenous provirus: chromosomal localization and evolutionary relationships.

Authors:  C O'Connell; S O'Brien; W G Nash; M Cohen
Journal:  Virology       Date:  1984-10-30       Impact factor: 3.616

10.  Retrovirus-like particles in EBV-negative Burkitt's lymphoma cell line but not in EBV-DNA-positive lines from patients with ataxia telangiectasia and Down's syndrome.

Authors:  M Kotler; H Balabanova; A Friedmann; Y Becker
Journal:  Br J Cancer       Date:  1979-04       Impact factor: 7.640

View more
  3 in total

1.  Gene transfer by viral vectors for gene therapy.

Authors:  Y Becker; G Darai
Journal:  J Mol Med (Berl)       Date:  1995-03       Impact factor: 4.599

Review 2.  Evolution and biological significance of human retroelements.

Authors:  C Leib-Mösch; W Seifarth
Journal:  Virus Genes       Date:  1995       Impact factor: 2.332

3.  Human endogenous retrovirus-K(II) envelope induction protects neurons during HIV/AIDS.

Authors:  Rakesh K Bhat; Wallis Rudnick; Joseph M Antony; Ferdinand Maingat; Kristofor K Ellestad; Blaise M Wheatley; Ralf R Tönjes; Christopher Power
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.